T0	Participants 0 56	Older patients with chronic myeloid leukemia (≥65 years)
T1	Participants 96 118	than younger patients:
T2	Participants 225 289	in older patients with chronic myeloid leukemia in chronic phase
T3	Participants 366 493	randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase.
T4	Participants 494 622	Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (≥65 years vs.
T5	Participants 623 633	<65 years)
T6	Participants 856 869	tolerability.
T7	Participants 870 909	A total of 828 patients were randomized
T8	Participants 922 928	IM800.
T9	Participants 929 1004	Seven hundred eighty-four patients were evaluable (IM400, 382; IM800, 402).
T10	Participants 1005 1077	One hundred ten patients (29 %) on IM400 and 83 (21 %) on IM800 were ≥65
T11	Participants 1429 1445	with which older
T12	Participants 1480 1498	later than younger